Quest Diagnostics Receives Mixed Analyst Ratings, Sees Upward Price Target

Quest Diagnostics, a leading diagnostic testing and information company, has received a range of ratings and price targets from various analyst firms. Despite these mixed reviews, the company's stock has seen significant price action, driven by its strong earnings report and potential for future growth. With a current market cap of $9.840 billion, Quest Diagnostics is a major player in the healthcare industry.

Key Takeaways:

• Bank of America set a $68.00 target price on Quest Diagnostics, while maintaining a hold rating on the stock.
• Goldman Sachs reiterated a buy rating on shares of Quest Diagnostics, with a $79.00 price target.
• Deutsche Bank upgraded shares of Quest Diagnostics from a hold rating to a buy rating, with a $75.00 price target.
• Seven investment analysts have rated the stock with a hold rating, while three have given a buy rating.
• The stock has a consensus rating of Hold and a consensus price target of $65.42.
• Quest Diagnostics' earnings per share beat analysts' estimates, reporting $1.10 earnings per share in the last quarter.
• The company's revenue was up 6.5% compared to the same quarter last year, with analysts predicting $4.07 earnings per share for the current fiscal year.

Statistics:

• Quest Diagnostics has a market cap of $9.840 billion.
• The stock's 50-day moving average is $64.86, while its 200-day moving average is $62.03.
• The company has a P/E ratio of 19.45.
• The dividend yield is 1.94%, with an annualized dividend of $1.32 per share.
• The ex-dividend date is Friday, January 9th, and the dividend is scheduled to be paid on Wednesday, January 28th.

Sources:

• Bank of America report issued on Monday
• Goldman Sachs research note on Thursday, December 18th
• Deutsche Bank research note on Thursday, November 13th
• Zacks research note on Thursday, October 30th
• Quest Diagnostics earnings report on Thursday, October 23rd
• 2014 Global Data Point
• SyndiGate Media Inc. (Syndigate.info)